BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idée JM, Ballet S, Corot C. T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. Invest Radiol 2015;50:473-80. [PMID: 26107651 DOI: 10.1097/RLI.0000000000000181] [Cited by in Crossref: 183] [Cited by in F6Publishing: 77] [Article Influence: 30.5] [Reference Citation Analysis]
Number Citing Articles
1 Smith TE, Steven A, Bagert BA. Gadolinium Deposition in Neurology Clinical Practice. Ochsner J 2019;19:17-25. [PMID: 30983897 DOI: 10.31486/toj.18.0111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
2 Kanda T, Oba H, Toyoda K, Furui S. Recent Advances in Understanding Gadolinium Retention in the Brain. AJNR Am J Neuroradiol 2016;37:E1-2. [PMID: 26494697 DOI: 10.3174/ajnr.A4586] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
3 Perrotta G, Metens T, Absil J, Lemort M, Manto M. Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study. J Neurol 2017;264:2277-83. [PMID: 28956156 DOI: 10.1007/s00415-017-8631-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 El-Khatib AH, Radbruch H, Trog S, Neumann B, Paul F, Koch A, Linscheid MW, Jakubowski N, Schellenberger E. Gadolinium in human brain sections and colocalization with other elements. Neurol Neuroimmunol Neuroinflamm 2019;6:e515. [PMID: 30568993 DOI: 10.1212/NXI.0000000000000515] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
5 Grahl S, Bussas M, Pongratz V, Kirschke JS, Zimmer C, Berthele A, Hemmer B, Mühlau M. T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis. Clin Neuroradiol 2021;31:235-43. [PMID: 32055874 DOI: 10.1007/s00062-020-00882-6] [Reference Citation Analysis]
6 Fretellier N, Granottier A, Rasschaert M, Grindel AL, Baudimont F, Robert P, Idée JM, Corot C. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. Invest Radiol 2019;54:61-71. [PMID: 30394964 DOI: 10.1097/RLI.0000000000000517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
7 Kanal E, Patton TJ, Krefting I, Wang C. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration. AJNR Am J Neuroradiol 2020;41:393-9. [PMID: 32115422 DOI: 10.3174/ajnr.A6448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nörenberg D, Schmidt F, Schinke K, Frenzel T, Pietsch H, Giese A, Ertl-Wagner B, Levin J. Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS One 2020;15:e0231495. [PMID: 32324769 DOI: 10.1371/journal.pone.0231495] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ngamcherdtrakul W, Morry J, Sangvanich T, Reda M, Bejan DS, Fryxell GE, Yantasee W. Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model. Sci Rep 2019;9:709. [PMID: 30679698 DOI: 10.1038/s41598-018-37348-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018;289:517-34. [PMID: 30204075 DOI: 10.1148/radiol.2018181151] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 30.3] [Reference Citation Analysis]
11 Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S. Distribution and chemical forms of gadolinium in the brain: a review. Br J Radiol 2017;90:20170115. [PMID: 28749164 DOI: 10.1259/bjr.20170115] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
12 Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am J Neuroradiol 2016;37:1192-8. [PMID: 26659341 DOI: 10.3174/ajnr.A4615] [Cited by in Crossref: 218] [Cited by in F6Publishing: 78] [Article Influence: 31.1] [Reference Citation Analysis]
13 Splendiani A, Corridore A, Torlone S, Martino M, Barile A, Di Cesare E, Masciocchi C. Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no? Insights Imaging 2019;10:82. [PMID: 31482392 DOI: 10.1186/s13244-019-0767-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pullicino R, Radon M, Biswas S, Bhojak M, Das K. A Review of the Current Evidence on Gadolinium Deposition in the Brain. Clin Neuroradiol 2018;28:159-69. [PMID: 29523896 DOI: 10.1007/s00062-018-0678-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
15 Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol 2017;52:396-404. [PMID: 28125438 DOI: 10.1097/RLI.0000000000000352] [Cited by in Crossref: 141] [Cited by in F6Publishing: 48] [Article Influence: 35.3] [Reference Citation Analysis]
16 Lee JY, Park JE, Kim HS, Kim SO, Oh JY, Shim WH, Jung SC, Choi CG, Kim SJ. Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: Multifactorial analysis in 385 patients. PLoS One 2017;12:e0183916. [PMID: 28859167 DOI: 10.1371/journal.pone.0183916] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
17 Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F. Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. Neuroimage 2019;186:308-20. [PMID: 30445148 DOI: 10.1016/j.neuroimage.2018.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Forslin Y, Martola J, Bergendal Å, Fredrikson S, Wiberg MK, Granberg T. Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. AJNR Am J Neuroradiol 2019;40:1265-73. [PMID: 31248867 DOI: 10.3174/ajnr.A6112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
19 Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol 2022. [PMID: 34997254 DOI: 10.1007/s00204-021-03189-8] [Reference Citation Analysis]
20 Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology. 2016;58:433-441. [PMID: 26873830 DOI: 10.1007/s00234-016-1658-1] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 14.7] [Reference Citation Analysis]
21 Celiker FB, Tumkaya L, Yilmaz A, Coskun ZO, Celiker M, Oghan F, Mercantepe T, Terzi S, Dursun E. Effects of gadolinium-based contrast agents on submandibular gland tissue in rats. Eur Arch Otorhinolaryngol 2018;275:1641-7. [PMID: 29605866 DOI: 10.1007/s00405-018-4959-7] [Reference Citation Analysis]
22 van der Molen AJ. Gadolinium Deposition in the Brain and Body. Journal of the Belgian Society of Radiology 2019;103:71. [DOI: 10.5334/jbsr.1945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ramalho J, Ramalho M, AlObaidy M, Nunes RH, Castillo M, Semelka RC. T1 Signal-Intensity Increase in the Dentate Nucleus after Multiple Exposures to Gadodiamide: Intraindividual Comparison between 2 Commonly Used Sequences. AJNR Am J Neuroradiol 2016;37:1427-31. [PMID: 27032972 DOI: 10.3174/ajnr.A4757] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
24 Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Reply. AJNR Am J Neuroradiol 2016;37:E42. [PMID: 26915565 DOI: 10.3174/ajnr.A4744] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
25 Guo BJ, Yang ZL, Zhang LJ. Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives. Front Mol Neurosci 2018;11:335. [PMID: 30294259 DOI: 10.3389/fnmol.2018.00335] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 16.3] [Reference Citation Analysis]
26 Kühn I, Maschke H, Großmann A, Hauenstein K, Weber MA, Zettl UK, Storch A, Walter U. Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients. Neurol Sci 2021. [PMID: 34735650 DOI: 10.1007/s10072-021-05702-4] [Reference Citation Analysis]
27 Garcia J, Liu SZ, Louie AY. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. Philos Trans A Math Phys Eng Sci 2017;375:20170180. [PMID: 29038383 DOI: 10.1098/rsta.2017.0180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
28 Khairinisa MA, Ariyani W, Tsushima Y, Koibuchi N. Effects of Gadolinium Deposits in the Cerebellum: Reviewing the Literature from In Vitro Laboratory Studies to In Vivo Human Investigations. Int J Environ Res Public Health 2021;18:7214. [PMID: 34299664 DOI: 10.3390/ijerph18147214] [Reference Citation Analysis]
29 Beomonte Zobel B, Quattrocchi CC, Errante Y, Grasso RF. Gadolinium-based contrast agents: did we miss something in the last 25 years? Radiol Med 2016;121:478-81. [PMID: 26706453 DOI: 10.1007/s11547-015-0614-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ayers-ringler J, Mcdonald JS, Connors MA, Fisher CR, Han S, Jakaitis DR, Scherer B, Tutor G, Wininger KM, Dai D, Choi D, Salisbury JL, Jannetto PJ, Bornhorst JA, Kadirvel R, Kallmes DF, Mcdonald RJ. Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration. Radiology. [DOI: 10.1148/radiol.210559] [Reference Citation Analysis]
31 Davies J, Marino M, Smith APL, Crowder JM, Larsen M, Lowery L, Castle J, Hibberd MG, Evans PM. Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure. Sci Rep 2021;11:13950. [PMID: 34230532 DOI: 10.1038/s41598-021-93147-2] [Reference Citation Analysis]
32 Eisele P, Alonso A, Szabo K, Ebert A, Ong M, Schoenberg SO, Gass A. Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: An observational study. Medicine (Baltimore) 2016;95:e4624. [PMID: 27684794 DOI: 10.1097/MD.0000000000004624] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 6.4] [Reference Citation Analysis]
33 Akai H, Yasaka K, Kunimatsu A, Nojima M, Inoue Y, Abe O, Ohtomo K, Kiryu S. The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Eur Radiol 2018;28:4128-33. [PMID: 29651770 DOI: 10.1007/s00330-018-5403-5] [Reference Citation Analysis]
34 Jost G, Frenzel T, Boyken J, Pietsch H. Impact of brain tumors and radiotherapy on the presence of gadolinium in the brain after repeated administration of gadolinium-based contrast agents: an experimental study in rats. Neuroradiology 2019;61:1273-80. [PMID: 31297571 DOI: 10.1007/s00234-019-02256-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Hoggard N, Roditi GH. T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition? Br J Radiol 2017;90:20160590. [PMID: 27653560 DOI: 10.1259/bjr.20160590] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
36 Jost G, Lenhard DC, Sieber MA, Lohrke J, Frenzel T, Pietsch H. Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents. Invest Radiol 2016;51:83-9. [PMID: 26606548 DOI: 10.1097/RLI.0000000000000242] [Cited by in Crossref: 117] [Cited by in F6Publishing: 47] [Article Influence: 19.5] [Reference Citation Analysis]
37 Unruh C, Van Bavel N, Anikovskiy M, Prenner EJ. Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks. Molecules 2020;25:E5762. [PMID: 33297578 DOI: 10.3390/molecules25235762] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rasschaert M, Idée JM, Robert P, Fretellier N, Vives V, Violas X, Ballet S, Corot C. Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. Invest Radiol 2017;52:255-64. [PMID: 28067754 DOI: 10.1097/RLI.0000000000000339] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
39 Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol 2017;52:324-33. [PMID: 28323657 DOI: 10.1097/RLI.0000000000000344] [Cited by in Crossref: 105] [Cited by in F6Publishing: 44] [Article Influence: 26.3] [Reference Citation Analysis]
40 Montagne A, Toga AW, Zlokovic BV. Blood-Brain Barrier Permeability and Gadolinium: Benefits and Potential Pitfalls in Research. JAMA Neurol 2016;73:13-4. [PMID: 26524294 DOI: 10.1001/jamaneurol.2015.2960] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
41 Robert P, Violas X, Grand S, Lehericy S, Idée JM, Ballet S, Corot C. Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats. Invest Radiol 2016;51:73-82. [PMID: 26606549 DOI: 10.1097/RLI.0000000000000241] [Cited by in Crossref: 152] [Cited by in F6Publishing: 57] [Article Influence: 25.3] [Reference Citation Analysis]
42 Boyken J, Frenzel T, Lohrke J, Jost G, Schütz G, Pietsch H. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats. Invest Radiol 2019;54:76-82. [PMID: 30358694 DOI: 10.1097/RLI.0000000000000522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 2018;17:1893-901. [PMID: 29970480 DOI: 10.1158/1535-7163.MCT-17-0600] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
44 Chen JW. Does Brain Gadolinium Deposition Have Clinical Consequence? Lessons from Animal Studies. Radiology 2021;301:417-9. [PMID: 34463556 DOI: 10.1148/radiol.2021211833] [Reference Citation Analysis]
45 Zhao K, Li S, Yi P, Guo Y, Yu Q, Zhu C, Feng Q, Du J, Zhang X, Feng Y. Detection of gadolinium deposition in cortical bone with ultrashort echo time T1 mapping: an ex vivo study in a rabbit model. Eur Radiol 2021;31:1569-77. [PMID: 32929642 DOI: 10.1007/s00330-020-07258-x] [Reference Citation Analysis]
46 Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol 2018;84:2522-34. [PMID: 30032482 DOI: 10.1111/bcp.13718] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
47 Minaeva O, Hua N, Franz ES, Lupoli N, Mian AZ, Farris CW, Hildebrandt AM, Kiernan PT, Evers LE, Griffin AD, Liu X, Chancellor SE, Babcock KJ, Moncaster JA, Jara H, Alvarez VE, Huber BR, Guermazi A, Latour LL, McKee AC, Soto JA, Anderson SW, Goldstein LE. Nonhomogeneous Gadolinium Retention in the Cerebral Cortex after Intravenous Administration of Gadolinium-based Contrast Agent in Rats and Humans. Radiology 2020;294:377-85. [PMID: 31769744 DOI: 10.1148/radiol.2019190461] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
48 Schöckel L, Balzer T, Pietsch H. [Increased signal intensities and gadolinium levels in the brain after administration of gadolinium-based MR contrast agents : Clinical observations and results from preclinical research]. Radiologe 2019;59:359-68. [PMID: 30887087 DOI: 10.1007/s00117-019-0511-z] [Reference Citation Analysis]
49 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29:365-76. [PMID: 27053146 DOI: 10.1007/s10534-016-9931-7] [Cited by in Crossref: 336] [Cited by in F6Publishing: 265] [Article Influence: 56.0] [Reference Citation Analysis]
50 Adin ME, Kleinberg L, Vaidya D, Zan E, Mirbagheri S, Yousem DM. REPLY. AJNR Am J Neuroradiol 2016;37:E3-4. [PMID: 26494696 DOI: 10.3174/ajnr.A4608] [Reference Citation Analysis]
51 Kanda T. The New Restrictions on the Use of Linear Gadolinium-based Contrast Agents in Japan. Magn Reson Med Sci 2019;18:1-3. [PMID: 29553066 DOI: 10.2463/mrms.e.2017-0176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
52 Hall AJ, Robertson AG, Hill LR, Rendina LM. Synthesis and tumour cell uptake studies of gadolinium(III)-phosphonium complexes. Sci Rep 2021;11:598. [PMID: 33436690 DOI: 10.1038/s41598-020-79893-9] [Reference Citation Analysis]
53 Koiso T, Yamamoto M, Watanabe S, Barfod BE. Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide. Neuroradiol J 2019;32:215-24. [PMID: 30924388 DOI: 10.1177/1971400919839646] [Reference Citation Analysis]
54 Acar T, Kaya E, Yoruk MD, Duzenli N, Senturk RS, Can C, Ozturk L, Tomruk C, Uyanikgil Y, Rybicki FJ. Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents. Jpn J Radiol 2019;37:458-65. [PMID: 30929137 DOI: 10.1007/s11604-019-00835-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
55 Mithal LB, Patel PS, Mithal D, Palac HL, Rozenfeld MN. Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Pediatr Radiol 2017;47:657-64. [PMID: 28283727 DOI: 10.1007/s00247-017-3810-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
56 Murphy DJ, Aghayev A, Steigner ML. Vascular CT and MRI: a practical guide to imaging protocols. Insights Imaging 2018;9:215-36. [PMID: 29541955 DOI: 10.1007/s13244-018-0597-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
57 Ariyani W, Khairinisa MA, Perrotta G, Manto M, Koibuchi N. The Effects of Gadolinium-Based Contrast Agents on the Cerebellum: from Basic Research to Neurological Practice and from Pregnancy to Adulthood. Cerebellum 2018;17:247-51. [PMID: 29196974 DOI: 10.1007/s12311-017-0903-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Federau C, Christensen S, Zun Z, Park SW, Ni W, Moseley M, Zaharchuk G. Cerebral blood flow, transit time, and apparent diffusion coefficient in moyamoya disease before and after acetazolamide. Neuroradiology 2017;59:5-12. [PMID: 27913820 DOI: 10.1007/s00234-016-1766-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
59 McDonald ES, Hammersley JA, Chou SH, Rahbar H, Scheel JR, Lee CI, Liu CL, Lehman CD, Partridge SC. Performance of DWI as a Rapid Unenhanced Technique for Detecting Mammographically Occult Breast Cancer in Elevated-Risk Women With Dense Breasts. AJR Am J Roentgenol 2016;207:205-16. [PMID: 27077731 DOI: 10.2214/AJR.15.15873] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
60 Huang H, Du X, He Z, Yan Z, Han W. Nanoparticles for Stem Cell Tracking and the Potential Treatment of Cardiovascular Diseases. Front Cell Dev Biol 2021;9:662406. [PMID: 34277609 DOI: 10.3389/fcell.2021.662406] [Reference Citation Analysis]
61 Devreux M, Henoumont C, Dioury F, Boutry S, Vacher O, Elst LV, Port M, Muller RN, Sandre O, Laurent S. Mn2+ Complexes with Pyclen-Based Derivatives as Contrast Agents for Magnetic Resonance Imaging: Synthesis and Relaxometry Characterization. Inorg Chem 2021;60:3604-19. [PMID: 33625836 DOI: 10.1021/acs.inorgchem.0c03120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Goischke HK. Safety assessment of gadolinium-based contrast agents (GBCAs) requires consideration of long-term adverse effects in all human tissues. Mult Scler J Exp Transl Clin 2017;3:2055217317704450. [PMID: 28607758 DOI: 10.1177/2055217317704450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Clough TJ, Jiang L, Wong KL, Long NJ. Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. Nat Commun 2019;10:1420. [PMID: 30926784 DOI: 10.1038/s41467-019-09342-3] [Cited by in Crossref: 90] [Cited by in F6Publishing: 57] [Article Influence: 30.0] [Reference Citation Analysis]
64 Langner S, Kromrey ML, Kuehn JP, Grothe M, Domin M. Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis. Eur Radiol 2017;27:3687-93. [PMID: 28289935 DOI: 10.1007/s00330-017-4777-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
65 Conte G, Preda L, Cocorocchio E, Raimondi S, Giannitto C, Minotti M, De Piano F, Petralia G, Ferrucci PF, Bellomi M. Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol 2017;27:4372-8. [PMID: 28357495 DOI: 10.1007/s00330-017-4810-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
66 Boyken J, Frenzel T, Lohrke J, Jost G, Pietsch H. Gadolinium Accumulation in the Deep Cerebellar Nuclei and Globus Pallidus After Exposure to Linear but Not Macrocyclic Gadolinium-Based Contrast Agents in a Retrospective Pig Study With High Similarity to Clinical Conditions. Invest Radiol 2018;53:278-85. [PMID: 29319556 DOI: 10.1097/RLI.0000000000000440] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
67 Robert P, Frenzel T, Factor C, Jost G, Rasschaert M, Schuetz G, Fretellier N, Boyken J, Idée JM, Pietsch H. Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative. Invest Radiol 2018;53:499-517. [PMID: 29659381 DOI: 10.1097/RLI.0000000000000467] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
68 Baliyan V, Verdini D, Meyersohn NM. Noninvasive aortic imaging. Cardiovasc Diagn Ther 2018;8:S3-S18. [PMID: 29850415 DOI: 10.21037/cdt.2018.02.01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Akai H, Miyagawa K, Takahashi K, Mochida-Saito A, Kurokawa K, Takeda H, Tsuji M, Sugawara H, Yasaka K, Kunimatsu A, Inoue Y, Abe O, Ohtomo K, Kiryu S. Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function: A Mouse Model. Radiology 2021;301:409-16. [PMID: 34463554 DOI: 10.1148/radiol.2021210892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Choi JW, Moon WJ. Gadolinium Deposition in the Brain: Current Updates.Korean J Radiol. 2019;20:134-147. [PMID: 30627029 DOI: 10.3348/kjr.2018.0356] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 13.8] [Reference Citation Analysis]
71 Dai L, Jones CM, Chan WTK, Pham TA, Ling X, Gale EM, Rotile NJ, Tai WC, Anderson CJ, Caravan P, Law GL. Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications. Nat Commun 2018;9:857. [PMID: 29487362 DOI: 10.1038/s41467-018-03315-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
72 Baroni RH, Bauab T Jr, Bittencourt LK, D'Ippolito G, Goldman SM, Hohgraefe Neto G, Manzella A, Rocha AJ, Sonoda LA, Takeda FS. Practical recommendations for the safe use of gadolinium in magnetic resonance imaging: a Delphi expert panel study. Radiol Bras 2020;53:216-22. [PMID: 32904664 DOI: 10.1590/0100-3984.2019.0074] [Reference Citation Analysis]
73 Bussi S, Coppo A, Botteron C, Fraimbault V, Fanizzi A, De Laurentiis E, Colombo Serra S, Kirchin MA, Tedoldi F, Maisano F. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging 2018;47:746-52. [PMID: 28730643 DOI: 10.1002/jmri.25822] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 13.6] [Reference Citation Analysis]
74 Stojanov DA. Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:818-9. [PMID: 26391361 DOI: 10.1007/s00330-015-4020-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
75 Richter H, Bücker P, Dunker C, Karst U, Kircher PR. Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents. PLoS One 2020;15:e0227649. [PMID: 32012163 DOI: 10.1371/journal.pone.0227649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
76 Bussi S, Coppo A, Celeste R, Fanizzi A, Fringuello Mingo A, Ferraris A, Botteron C, Kirchin MA, Tedoldi F, Maisano F. Macrocyclic MR contrast agents: evaluation of multiple-organ gadolinium retention in healthy rats. Insights Imaging 2020;11:11. [PMID: 32020385 DOI: 10.1186/s13244-019-0824-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
77 Pinter NK, Klein JP, Mechtler LL. Potential Safety Issues Related to the Use of Gadolinium-based Contrast Agents. Continuum (Minneap Minn) 2016;22:1678-84. [PMID: 27740994 DOI: 10.1212/CON.0000000000000378] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
78 Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H. Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol 2017;27:2877-85. [PMID: 27832312 DOI: 10.1007/s00330-016-4654-2] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 14.3] [Reference Citation Analysis]
79 Kartamihardja AA, Nakajima T, Kameo S, Koyama H, Tsushima Y. Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model. Br J Radiol 2016;89:20160509. [PMID: 27459250 DOI: 10.1259/bjr.20160509] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
80 Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X. Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol 2017;38:1486-93. [PMID: 28619842 DOI: 10.3174/ajnr.A5253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
81 Foran P, Hwang S, Mazaheri Y, Panicek D. High-Signal Bladder Urine at T1-Weighted MR Imaging Performed 1-7 Days After a Prior Gadolinium-Enhanced MRI: Prevalence and Correlation with Renal Function. BJR Open 2019;1:20180030. [PMID: 32864561 DOI: 10.1259/bjro.20180030] [Reference Citation Analysis]
82 Kinner S, Schubert TB, Bruce RJ, Rebsamen SL, Diamond CA, Reeder SB, Rowley HA. Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy. AJNR Am J Neuroradiol 2018;39:24-30. [PMID: 29146718 DOI: 10.3174/ajnr.A5453] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
83 Thaler C, Schneider T, Sedlacik J, Kutzner D, Stellmann JP, Heesen C, Fiehler J, Siemonsen S. T1w dark blood imaging improves detection of contrast enhancing lesions in multiple sclerosis. PLoS One 2017;12:e0183099. [PMID: 28797082 DOI: 10.1371/journal.pone.0183099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
84 Labriet H, Nemoz C, Renier M, Berkvens P, Brochard T, Cassagne R, Elleaume H, Estève F, Verry C, Balosso J, Adam JF, Brun E. Significant dose reduction using synchrotron radiation computed tomography: first clinical case and application to high resolution CT exams. Sci Rep 2018;8:12491. [PMID: 30131501 DOI: 10.1038/s41598-018-30902-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
85 Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J, Fredrikson S, Kristoffersen-Wiberg M, Granberg T. Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. AJNR Am J Neuroradiol 2017;38:1311-6. [PMID: 28495943 DOI: 10.3174/ajnr.A5211] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 7.2] [Reference Citation Analysis]
86 Karabulut N. Consider Risk for Gadolinium Retention in the Brain When Using Gadolinium-based Contrast Media. Radiographics 2016;36:620-1. [PMID: 26963466 DOI: 10.1148/rg.2016150244] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]